ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

ELOX Eloxx Pharmaceuticals Inc

3.82
0.00 (0.00%)
05 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Eloxx Pharmaceuticals Inc ELOX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.00 0.00% 3.82 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
3.82
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
16/4/202406:30GLOBEEloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program..
01/4/202415:02EDGAR2Form NT 10-K - Notification of inability to timely file Form..
29/3/202415:11EDGAR2Form 8-K - Current report
21/3/202413:20EDGAR2Form 25-NSE - Notification filed by national security..
14/3/202415:30EDGAR2Form 8-K - Current report
13/3/202410:42GLOBEAlmirall and Eloxx Pharmaceuticals Enter into Exclusive..
26/1/202415:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/1/202415:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/1/202415:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/1/202415:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202420:44EDGAR2Form S-3 - Registration statement under Securities Act of..
24/1/202416:11EDGAR2Form S-8 - Securities to be offered to employees in employee..
09/1/202416:10EDGAR2Form 8-K - Current report
28/12/202315:11EDGAR2Form 8-K - Current report
13/11/202315:15GLOBEEloxx Pharmaceuticals Reports Third Quarter 2023 Financial..
16/10/202316:26EDGAR2Form 8-K - Current report
09/10/202307:00GLOBEEloxx Pharmaceuticals Reports Additional Confirmation that..
20/9/202315:05EDGAR2Form 8-K - Current report
20/9/202312:26EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
19/9/202307:00GLOBEEloxx Pharmaceuticals Announces $2 Million Registered Direct..
18/9/202307:05EDGAR2Form 8-K - Current report
18/9/202306:00GLOBEEloxx Pharmaceuticals Reports Independent Confirmation of..
15/9/202316:15EDGAR2Form 8-K - Current report
07/9/202309:14EDGAR2Form 8-K - Current report
07/9/202308:00GLOBEEloxx Pharmaceuticals Provides Program Updates on ELX-02 and..
29/8/202315:32EDGAR2Form 8-K - Current report
21/8/202315:50EDGAR2Form 8-K - Current report
14/8/202310:56EDGAR2Form 8-K - Current report
14/8/202307:30GLOBEEloxx Pharmaceuticals Reports Second Quarter 2023 Financial..
14/8/202307:00GLOBEEloxx Pharmaceuticals Reports Drug Response in All Patients..
11/8/202315:11EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
11/8/202315:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/8/202315:01EDGAR2Form 8-K - Current report
03/8/202308:26GLOBEEloxx Pharmaceuticals Granted Extension by Nasdaq to Regain..
13/7/202307:43EDGAR2Form 8-K - Current report
10/7/202308:00GLOBEEloxx Pharmaceuticals Announces Publication Demonstrating..
28/6/202308:00GLOBEEloxx Pharmaceuticals Key Opinion Leader Event Highlights..
21/6/202312:30GLOBEEloxx Pharmaceuticals to Host Investor and Analyst Call on..
21/6/202308:00GLOBEEloxx Pharmaceuticals Highlights Recent Alport Syndrome..
14/6/202315:53GLOBEEloxx Pharmaceuticals Announces Final Data Assessment from..
06/6/202307:30GLOBEEloxx Pharmaceuticals Granted Extension by Nasdaq to Regain..
01/6/202308:10GLOBEAtossa Appoints Life Sciences Financial and Operations..
24/5/202307:00GLOBEEloxx Pharmaceuticals Intends to Advance ELX-02 into Pivotal..
15/5/202315:30GLOBEEloxx Pharmaceuticals Reports First Quarter 2023 Financial..

Su Consulta Reciente

Delayed Upgrade Clock